Evidence map›Paper›PMID 37683902›Full record

ArticleProtein expression and purification2024

Optimized expression and purification of a human adenosine deaminase in E. coli and characterization of its Asp8Asn variant.

Maria Rain Jennings, Soohyon Min, Grace S Xu, Kassandra Homayuni, Bhavana Suresh, Yusef Amir Haikal, John Blazeck

Open access · greenAbstract read
In one paragraph

Article in Protein expression and purification, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme.Journal of visualized experiments : JoVE · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maria Rain JenningsSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Soohyon MinSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Grace S XuSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Kassandra HomayuniSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Bhavana SureshSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Yusef Amir HaikalSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
John BlazeckSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA. Electronic address: john.blazeck@chbe.gatech.edu.
Georgia Institute of Technology · US

Funding

Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI FU, HAIAN · 2019 to 2024
$10.1M
Synthetic metabolism to armor and enhance a new class of cell therapiesDP2CA280622 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI BLAZECK, JOHN JAMES · 2022 to 2025
$2.3M
NCI NIH HHS DP2 CA280622NCI NIH HHS P50 CA217691
6 · The paper itself

Abstract

Homo sapiens adenosine deaminase isoform 1 (HsADA1) hydrolyzes adenosine and 2-deoxyadenosine as a key step in the purine nucleoside salvage pathway. Some HsADA1 mutations have severe deleterious effects, as is the case in a severe combined immunodeficiency resulting from loss of enzyme activity (ADA-SCID). Other mutations that reduce enzyme activity, for instance the Asp8Asn (D8N) variant, do not cause ADA-SCID but are correlated with other consequences to health. To ease further study of HsADA1 and its variants, we optimized an inexpensive, recombinant expression process in an Escherichia coli host through multiplexed parameter testing enabled by a lysate-based microtiter plate assay. We demonstrate the importance of gene codon usage, induction time and temperature, and alcohol supplementation towards improving enzyme yield to a final titer of 5 mg per liter of culture. We further show that use of a double-histidine-tag (his-tag) system greatly improves purity. We then utilize our expression and purification framework to produce the HsADA1 D8N variant, which had previously not been purified to homogeneity. We confirm that the D8N variant is ∼30% less active than the wildtype HsADA1 and show that it better retains its activity in human serum. Additionally, we show that both HsADA1 and the D8N variant have heightened activity in serum, driven in part by a previously undescribed phenomenon involving albumin. Therefore, this work presents a valuable process to produce HsADA1 that allows for insights into it and its variants' behavior. We also confirm the utility of lysate-based activity assays towards finding optimal E. coli expression conditions for enzymes and show how fusing his-tags in tandem can enhance product purity.

Indexed as

Adenosine DeaminaseEscherichia coliSevere Combined ImmunodeficiencyAgammaglobulinemiaHumansRecombinant ProteinsAdenosine DeaminaseRecombinant ProteinsAdenosine deaminaseBacterial lysate screeningDouble-his-tag

Identifiers

PMID37683902
PMCPMC10664833
OpenAlexW4386499082

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.